San Francisco startup Framework Therapeutics can also be working on an oral, after-every day GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June each time a mid-stage study showed common weight loss of all over 6% and it strategies to begin An additional mid-phase trial in the direction of the top of this calendar